Prognostic value of ABO blood groups in upfront operated pancreatic ductal adenocarcinomas.


Journal

Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285

Informations de publication

Date de publication:
18 Sep 2024
Historique:
received: 06 08 2024
accepted: 03 09 2024
medline: 25 9 2024
pubmed: 25 9 2024
entrez: 25 9 2024
Statut: epublish

Résumé

Pancreatic ductal adenocarcinoma (PDAC) has been shown to have a lower incidence in patients with blood group O. It is currently uncertain if patients with group O have a better prognosis after pancreatectomy. This study assessed the overall survival (OS) and disease-free survival (DFS) of PDAC patients who underwent upfront pancreatoduodenectomy based on ABO blood groups. A cross-sectional study was performed including patients from two university centers. All consecutive head PDAC patients who underwent upfront pancreatoduodenectomy from 2000 to 2016 were included. OS and DFS were compared between blood groups A, B, AB, and O using Kaplan-Meier curves and log-rank tests. A total of 438 patients were included (215 women, median age 67). Pre- and intraoperative details were comparable between all subgroups. Median OS did not differ between the four blood groups (A: 23 months, 95% CI 18-28; B: 32, 95% CI 20-44; AB: 37, 95% CI 18-56 and O: 26, 95% CI 20-32, p = 0.192). Median DFS were also similar (A: 19 months, 95% CI 15-23; B: 26, 95% CI 19-33; AB: 35, 95% CI 15-55 and O: 22, 95% CI 15-29, p = 0.441). There was no OS difference between O and non-O groups (median: 26 months, 95% CI 20-33 vs. 25 months, 95% CI 20-30, p = 0.773). On multivariable analysis blood groups were not prognostic of OS. Only lymph node involvement, tumor differentiation, and adjuvant chemotherapy were independent prognostic factors. OS and DFS were similar between all four blood groups after pancreatoduodenectomy. Independent predictors of OS were associated with tumor characteristics and adjuvant treatment.

Identifiants

pubmed: 39320512
doi: 10.1007/s00423-024-03469-8
pii: 10.1007/s00423-024-03469-8
doi:

Substances chimiques

ABO Blood-Group System 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

282

Informations de copyright

© 2024. The Author(s).

Références

Kamisawa T, Wood LD, Itoi T, Takaori K (2016) Pancreatic cancer. Lancet 388:73–85. https://doi.org/10.1016/S0140-6736(16)00141-0
doi: 10.1016/S0140-6736(16)00141-0 pubmed: 26830752
Strobel O, Lorenz P, Hinz U et al (2022) Actual five-year Survival after Upfront Resection for pancreatic ductal adenocarcinoma: who beats the odds? Ann Surg 275:962–971. https://doi.org/10.1097/SLA.0000000000004147
doi: 10.1097/SLA.0000000000004147 pubmed: 32649469
Belfiori G, Crippa S, Francesca A et al (2021) Long-term survivors after Upfront Resection for pancreatic ductal adenocarcinoma: an actual 5-Year analysis of Disease-Specific and Post-recurrence Survival. Ann Surg Oncol 28:8249–8260. https://doi.org/10.1245/s10434-021-10401-7
doi: 10.1245/s10434-021-10401-7 pubmed: 34258720
Wolpin BM, Chan AT, Hartge P et al (2009) ABO blood group and the risk of pancreatic cancer. J Natl Cancer Inst 101:424–431. https://doi.org/10.1093/jnci/djp020
doi: 10.1093/jnci/djp020 pubmed: 19276450 pmcid: 2657095
Greer J-B, Yazer M-H, Raval J-S et al (2010) Significant association between ABO blood group and pancreatic cancer. World J Gastroenterol 16:5588–5591. https://doi.org/10.3748/wjg.v16.i44.5588
doi: 10.3748/wjg.v16.i44.5588 pubmed: 21105191 pmcid: 2992676
Risch HA, Lu L, Wang J et al (2013) ABO blood group and risk of pancreatic cancer: a study in Shanghai and meta-analysis. Am J Epidemiol 177:1326–1337. https://doi.org/10.1093/aje/kws458
doi: 10.1093/aje/kws458 pubmed: 23652164 pmcid: 3732019
Amundadottir L, Kraft P, Stolzenberg-Solomon RZ et al (2009) Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 41:986–990. https://doi.org/10.1038/ng.429
doi: 10.1038/ng.429 pubmed: 19648918 pmcid: 2839871
Nakao M, Matsuo K, Hosono S et al (2011) ABO blood group alleles and the risk of pancreatic cancer in a Japanese population. Cancer Sci 102:1076–1080. https://doi.org/10.1111/j.1349-7006.2011.01907.x
doi: 10.1111/j.1349-7006.2011.01907.x pubmed: 21306478 pmcid: 11159622
Williams H, Jajja MR, Hashmi SS et al (2020) Association of ABO blood group with survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma. HPB (Oxford) 22:1557–1562. https://doi.org/10.1016/j.hpb.2020.01.004
doi: 10.1016/j.hpb.2020.01.004 pubmed: 32146119
Demir IE, Jäger C, Schlitter AM et al (2018) R0 Versus R1 resection matters after Pancreaticoduodenectomy, and less after distal or total pancreatectomy for pancreatic Cancer. Ann Surg 268:1058–1068. https://doi.org/10.1097/SLA.0000000000002345
doi: 10.1097/SLA.0000000000002345 pubmed: 28692477
Sohn TA, Yeo CJ, Cameron JL et al (2000) Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 4:567–579. https://doi.org/10.1016/s1091-255x(00)80105-5
doi: 10.1016/s1091-255x(00)80105-5 pubmed: 11307091
Dindo D, Demartines N, Clavien P-A (2004) Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205–213
doi: 10.1097/01.sla.0000133083.54934.ae pubmed: 15273542 pmcid: 1360123
Slankamenac K, Graf R, Barkun J et al (2013) The comprehensive complication index: a novel continuous scale to measure surgical morbidity. Ann Surg 258:1–7. https://doi.org/10.1097/SLA.0b013e318296c732
doi: 10.1097/SLA.0b013e318296c732 pubmed: 23728278
Campbell F, Cairns A, Duthie F et al (2019) G091-Dataset for histopathological reporting of carcinomas of the pancreas, ampulla of Vater and common bile duct. https://www.rcpath.org/static/34910231-c106-4629-a2de9e9ae6f87ac1/G091-Dataset-for-histopathological-reporting-of-carcinomas-of-the-pancreas-ampulla-of-Vater-and-common-bile-duct.pdf
El Jellas K, Hoem D, Hagen KG et al (2017) Associations between ABO blood groups and pancreatic ductal adenocarcinoma: influence on resection status and survival. Cancer Med 6:1531–1540. https://doi.org/10.1002/cam4.1097
doi: 10.1002/cam4.1097 pubmed: 28556564 pmcid: 5504338
Wang D, Wang Z, Zhang L et al (2012) Are risk factors associated with outcomes in pancreatic cancer? PLoS ONE 7:e41984. https://doi.org/10.1371/journal.pone.0041984
doi: 10.1371/journal.pone.0041984 pubmed: 22911869 pmcid: 3404018
Khalil K, Bansal S, Ayaani S et al (2018) Does blood group affect survival following pancreatoduodenectomy for periampullary malignancy? HPB (Oxford) 20:848–853. https://doi.org/10.1016/j.hpb.2018.03.009
doi: 10.1016/j.hpb.2018.03.009 pubmed: 29705345
Rahbari NN, Bork U, Hinz U et al (2012) AB0 blood group and prognosis in patients with pancreatic cancer. BMC Cancer 12:319. https://doi.org/10.1186/1471-2407-12-319
doi: 10.1186/1471-2407-12-319 pubmed: 22838843 pmcid: 3488322
Hakomori S (1999) Antigen structure and genetic basis of histo-blood groups a, B and O: their changes associated with human cancer. Biochim Biophys Acta 1473:247–266. https://doi.org/10.1016/s0304-4165(99)00183-x
doi: 10.1016/s0304-4165(99)00183-x pubmed: 10580143
Parra-Robert M, Santos VM, Canis SM et al (2018) Relationship between CA 19.9 and the Lewis phenotype: options to improve diagnostic efficiency. Anticancer Res 38:5883–5888. https://doi.org/10.21873/anticanres.12931
doi: 10.21873/anticanres.12931 pubmed: 30275214
Luo G, Jin K, Deng S et al (2021) Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter. Biochim Biophys Acta Rev Cancer 1875:188409. https://doi.org/10.1016/j.bbcan.2020.188409
doi: 10.1016/j.bbcan.2020.188409 pubmed: 32827580
Barbalic M, Dupuis J, Dehghan A et al (2010) Large-scale genomic studies reveal central role of ABO in sP-selectin and sICAM-1 levels. Hum Mol Genet 19:1863–1872. https://doi.org/10.1093/hmg/ddq061
doi: 10.1093/hmg/ddq061 pubmed: 20167578 pmcid: 2850624
Melzer D, Perry JRB, Hernandez D et al (2008) A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet 4:e1000072. https://doi.org/10.1371/journal.pgen.1000072
doi: 10.1371/journal.pgen.1000072 pubmed: 18464913 pmcid: 2362067
Paterson AD, Lopes-Virella MF, Waggott D et al (2009) Genome-wide association identifies the ABO blood group as a major locus associated with serum levels of soluble E-selectin. Arterioscler Thromb Vasc Biol 29:1958–1967. https://doi.org/10.1161/ATVBAHA.109.192971
doi: 10.1161/ATVBAHA.109.192971 pubmed: 19729612 pmcid: 3147250

Auteurs

Gaëtan-Romain Joliat (GR)

Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne (UNIL), Rue du Bugnon 46, Lausanne, 1011, Switzerland. gaetan-romain.joliat@chuv.ch.
Graduate School of Health Sciences, University of Bern, Bern, Switzerland. gaetan-romain.joliat@chuv.ch.

Ismail Labgaa (I)

Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne (UNIL), Rue du Bugnon 46, Lausanne, 1011, Switzerland.

David Martin (D)

Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne (UNIL), Rue du Bugnon 46, Lausanne, 1011, Switzerland.

Dionisios Vrochides (D)

Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, Carolinas Medical Center, Charlotte, USA.

Markus Schäfer (M)

Department of Visceral Surgery, Lausanne University Hospital CHUV, University of Lausanne (UNIL), Rue du Bugnon 46, Lausanne, 1011, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH